Login

Journal Image
Recent Patents on Anti-Infective Drug Discovery
ISSN (Print): 1574-891X
ISSN (Online): 2212-4071
VOLUME: 3
ISSUE: 2
DOI: 10.2174/157489108784746597      Price:  $100









NS5A - From Obscurity to New Target for HCV Therapy

img
Author(s): Uli Schmitz and Seng-Lai Tan
Pages 77-92 (16)
Abstract:
The hepatitis C virus (HCV) non-structural 5A (NS5A) protein is essential for viral RNA replication and may play a role in subverting host intracellular signaling pathways. Although no intrinsic enzymatic activity has been ascribed to NS5A, this proline-rich hydrophilic phosphoprotein is likely to exert its functions by interacting with viral and cellular factors. Recent studies using the HCV replicon cell culture system as a model for HCV RNA replication as well as for high-throughput screening of pharmacological inhibitors have revealed blockade of NS5A as a promising therapeutic strategy for the treatment of HCV. This review will summarize our progress in understanding the role of NS5A in HCV RNA replication and will introduce the most recent patents on inhibitors of NS5A.
Keywords:
HCV, NS5A, antivirals, HCV inhibitors, hyperphosphorylation
Affiliation:
Genelabs Technologies, Inc.,505 Penobscot Drive, Redwood City, CA 94063, USA.